Skip to content
Tech

Chinese Scientist Chen Zhu Receives 2026 Shaw Prize For Leukaemia Research

China News Editorial team · AI-written, reviewed under our editorial standards · · Reading time 9min read · Views 0 ·
Key — Chinese scientist Chen Zhu and French scientists Anne Dejean and Hugues de Thé received the 2026 Shaw Prize for transforming Acute Promyelocytic Leukaemia treatment.

Chinese scientist Chen Zhu, French scientist Anne Dejean, and French scientist Hugues de Thé received the 2026 Shaw Prize in Life Science and Medicine. This prestigious award recognizes transformative research that converted Acute Promyelocytic Leukaemia from a deadly condition into a highly treatable disease. The award ceremony took place in Hong Kong. The Shaw Prize in Life Science and Medicine represents one of the world's most prestigious scientific honors. The recognition highlights significant medical breakthroughs achieved by these researchers. These advancements have profoundly impacted global patient outcomes. The award ceremony celebrated these scientific achievements in Hong Kong.

Transforming Leukaemia Treatment

The research developed by the scientists transformed Acute Promyelocytic Leukaemia from a deadly disease into a highly treatable one. More than 90 percent of Acute Promyelocytic Leukaemia patients now survive beyond five years following these treatments. This dramatic improvement in survival rates represents a monumental achievement in oncology. The scientific community celebrates these life-saving medical innovations. The success of the research provides hope to millions of patients worldwide. The transformation of this deadly disease into a manageable condition is a testament to rigorous scientific inquiry.

Early Research and Discovery

Chinese scientist Chen Zhu began his interest in Acute Promyelocytic Leukaemia in the early 1980s. At that time, a diagnosis of Acute Promyelocytic Leukaemia carried an 80 percent risk of death. During this period, Chen Zhu and his colleagues explored an alternative treatment approach inspired by traditional Chinese philosophy. This innovative exploration led to the discovery of All-Trans Retinoic Acid, a specific vitamin A derivative. The drug targets abnormal leukaemia cells within the body.

Clinical Breakthroughs and Collaboration

The drug All-Trans Retinoic Acid demonstrated remarkable efficacy in clinical settings. A five-year-old girl with terminal Acute Promyelocytic Leukaemia achieved complete remission after only weeks of treatment. This successful case illustrated the drug's potent therapeutic potential. The next major breakthrough involved collaboration with French researchers. This international partnership combined expertise from different scientific backgrounds. The collaboration further advanced the understanding of leukaemia biology.

Scientific Collaboration and Future Work

The collaboration with French researchers complemented a separate discovery made in Harbin. The Harbin discovery involved scientists investigating the specific molecular mechanisms of the disease. Chinese scientist Chen Zhu stated that international cooperation is central to the achievement and empowers scientists to decode life's mysteries. This statement underscores the importance of global scientific partnerships in solving complex medical challenges. The Shaw Prize recognizes this spirit of international scientific endeavor.

The scientific community acknowledges the profound impact of this research on patient survival rates. The transformation of Acute Promyelocytic Leukaemia from a fatal diagnosis to a highly treatable condition represents a major victory for medical science. The award recognizes the dedication and perseverance of Chen Zhu, Anne Dejean, and Hugues de Thé. These scientists have fundamentally changed the prognosis for patients suffering from this aggressive blood cancer.

Glossary

  • Harbin — The Harbin discovery involved scientists investigating the specific molecular mechanisms of the disease.
  • Acute Promyelocytic Leukaemia — This award recognizes transformative research that converted Acute Promyelocytic Leukaemia from a deadly condition into a highly treatable disease. More than 90 percent of Acute Promyelocytic Leukaemia patients now survive beyond five years following these treatments.
  • Shaw Prize in Life Science and Medicine — The Shaw Prize in Life Science and Medicine represents one of the world's most prestigious scientific honors. The recognition highlights significant medical breakthroughs achieved by these researchers.

This article was written with AI assistance from multiple news reports and is reviewed by our editors under our editorial principles. Editorial Standards · Tips & Contact

How did you like this post?

Comments 0

Be the first to comment

Contact us

← China News Home
China News Get new posts by emailSubscribe to receive new content via email. Unsubscribe anytime.
Was this helpful?Share it with friends & social